Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Sheng Lin-Gibson (Fed)

Dr. Sheng Lin-Gibson is the Chief of the Biosystems and Biomaterials Division (BBD) at the National Institute of Standards and Technology (NIST).  BBD has a multidisciplinary technical portfolio that includes genomic measurements, synthetic biology, regenerative medicine and advanced therapies, biomaterials, diagnostics, and complex microbial systems. BBD carries out its mission through fundamental research in measurement science, the development of new technologies, and the deployment of new measurement solutions, including reference materials and data.

More information about BBD:

About BBD 
Core capabilities
Primary focus areas
Standards and reference materials

Honors and Awards

  • Gears of Government Award: Biotechnology Standards Leadership (2019)
  • Department of Commerce (DoC) Gold Medal Award: Biotechnology Standards Leadership (2019)
  • Department of Commerce (DoC) Bronze Medal: Cell Counting Measurements (2017)
  • Department of Commerce (DoC) Bronze Medal: Metrology for Dental Materials (2014)
  • NIST Sigma Xi Young Investigator Award (2011)
  • National Academy of Engineering (NAE) China-America Frontiers of Engineering (2011)
  • Department of Commerce (DoC) Bronze Medal: Combinatorial Testing of Biomaterials (2010)
  • NIST/NRC Postdoctoral Research Fellowship

Selected Publications: (Out of 200+ Publications)

S. Lin-Gibson and V. Srinivasan, "Recent Industrial Roadmaps to Enable Smart Manufacturing of Biopharmaceuticals," IEEE Transactions on Automation Science and Engineering, doi: 10.1109/TASE.2019.2951018.

K Czechowska, J Lannigan, L Wang, J Arcidiacono et al, Cyt‐Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2018 Conference Workshops,” Cytometry Part A, 2019, 95(6), 598-644.

S Sarkar, L Pierce, S Lin-Gibson, SP Lund, “Standards landscape in cell counting: implications for cell & gene therapy” Cell Gene Ther. Insights, 2019, 5 (1), 117-31

S Sarkar, S Lin‐Gibson, "Computational Design of Photocured Polymers Using Stochastic Reaction–Diffusion Simulation” Advanced Theory and Simulations, 2018, 1(7), 1800028

J.A. Arcidiacono, S.R. Bauer, D.S. Kaplan, C.M. Allocca, S. Sarkar, S. Lin-Gibson, “FDA and NIST collaboration on standards development activities supporting innovation and translation of regenerative medicine products,” Cytotherapy, 2018, 20 (6), 779-784.

S Lin-Gibson, S Sarkar, JT Elliott, “Summary of the National Institute of Standards and Technology and US Food And Drug Administration cell counting workshop: Sharing practices in cell counting measurements”, Cytotherapy, 2018, 20 (6), 785-795.

S Sarkar, SP Lund, R Vyzasatya, P Vanguri, JT Elliott, AL Plant “Evaluating the quality of a cell counting measurement process via a dilution series experimental design,” 2017, Cytotherapy 19 (12), 1509-1521.

D López Pérez, PJ Baker, AL Pintar, J Sun, NJ Lin, S Lin-Gibson, “Experimental and statistical methods to evaluate antibacterial activity of a quaternary pyridinium salt on planktonic, biofilm-forming, and biofilm states,” Biofouling 33 (3), 222-234.

S Lin-Gibson, B Hanrahan, S Matosevic, A Schnitzler, J Zhang, ...”Points to consider for cell manufacturing equipment and components” Cell Gene Therapy Insights, 2017, 3 (10), 793-805.

S Lin-Gibson, S Sarkar, Y Ito, “Defining quality attributes to enable measurement assurance for cell therapy products” Cytotherapy, 2016, 18 (10), 1241-1244.

CG Simon Jr, S Lin-Gibson, JT Elliott, S Sarkar, AL Plant “Strategies for achieving measurement assurance for cell therapy products,” Stem Cells Translational Medicine, 2016, 5 (6), 705-708

Publications

Standards and Metrology for Viral Vectors as Molecular Tools: Outcomes from a CCQM Workshop

Author(s)
Janathan Campbell, Neil Almond, Y Bae, Ravneet Bhuller, Andrea Briones, S-Y CHO, Megan Cleveland, Thomas Cleveland, Francis Galaway, Hua-Jun He, U Herbrand, Jim Huggett, Sarah Kempster, Ibolya Kepiro, Afifa Khan, Edward Kwee, Wilson Li, Sheng Lin-Gibson, Luise Luckau, Caterina Minelli, M Ryadnov, I Searing, Lili Wang, Alexandra Whale, Julian Braybrook
Viral vectors are agents enabling gene transfer and genome editing and have widespread utility across the healthcare and biotechnology sectors. In January 2023

Monoclonal Antibodies as SARS-CoV-2 Serology Standards: Experimental Validation and Broader Implications for Correlates of Protection

Author(s)
Lili Wang, Paul Patrone, Anthony Kearsley, Jerilyn Izac, Adolfas Gaigalas, John Prostko, Hang Xie, Linhua Tian, Elzafir Elsheikh, Edward Kwee, Troy Kemp, Simon Jochum, Natalie Thornburg, Clifford McDonald, Adi Gundlapalli, Sheng Lin-Gibson
COVID-19 has highlighted the need for more accurate and reproducible measurements of humoral immunity, including antibody levels and neutralization potential

Report from the 2022 NIST Rapid Microbial Testing Methods (RMTM) Workshop

Author(s)
Stephanie Servetas, Nancy Lin, Nadratun Chowdhury, Scott Jackson, Jason Kralj, Sheng Lin-Gibson, Melody Sanders, Tara Eskandari
Safety and quality of advanced therapies, including cellular, gene, and tissue-engineered medical products, is paramount for success of these products
Created August 28, 2019, Updated December 8, 2022